Fintech News

Duff & Phelps Elects Jason Wingard to Board of Directors

RSA® Emerges as Independent Company Following Completion of Acquisition by Symphony Technology Group

Duff & Phelps, the world’s premier provider of governance, risk and transparency solutions, today announced that Dr. Jason Wingard has been appointed to the firm’s board of directors.

Dr. Wingard is Dean Emeritus and Professor of Human Capital Management at the Columbia University School of Professional Studies. He is a globally renowned expert and thought leader in the areas of organizational strategy, leadership development and the future of work. Prior to Columbia, Dr. Wingard served as Chief Learning Officer at Goldman Sachs where he oversaw the acclaimed Pine Street Leadership Development Group and Goldman Sachs University, and was responsible for the strategy and implementation of learning and leadership development solutions for the firm’s partners, global workforce and clients. Before that, he served as Vice Dean of the Wharton School at the University of Pennsylvania, where he was the head of Executive Education and oversaw one of the world’s largest providers of leadership and management development. He also served as Senior Vice President of ePals, Inc., which is now Cricket Media, the world’s leading provider of interactive/collaborative learning products, and President and CEO of the ePals Foundation.

Prior to joining ePals, Dr. Wingard was Executive Director of the Stanford Educational Leadership Institute at Stanford University. He has also served in a variety of cross-functional executive and consulting roles for organizations including the Aspen Institute, the Vanguard Group and Silicon Graphics, Inc.

Noah Gottdiener, Chief Executive Officer of Duff & Phelps, commented, “Earlier this year, Duff & Phelps entered an exciting new chapter in our ownership, and with this came the need for an independent board member to help build our firm’s next generation of leaders. Jason is an expert in organizational development, and his appointment comes at a transformative time—both for our company and society at large. I look forward to working closely with Jason, and to welcoming the new perspectives he will bring as a member of our board.”

Dr. Wingard added, “To remain competitive in the contemporary market economy, companies must increasingly adapt—fiscally, operationally, and culturally—more than was previously required. The board’s responsibility is to both sponsor that innovation and be held accountable for targeted metrics of success. Duff & Phelps is in a unique position to advance an aggressive change agenda, and I am thrilled to join Noah, Jake and the rest of the board to support and expand the firm’s trajectory of positive performance and values of collaboration, transparency and integrity.”

In addition to Duff & Phelps, Dr. Wingard serves as an advisor to PepsiCo and JUST Capital and is a member of the board of directors for Tides, Roundabout Theater Company, Building 21 and the Education Board Foundation. He previously served on the board of directors for United Cerebral Palsy and the National Center for Fathering.

Dr. Wingard is the eighth, and first independent, member of the Duff & Phelps board of directors, which includes Noah Gottdiener, Chief Executive Officer of Duff & Phelps; Jacob Silverman, President of Duff & Phelps; Jacqueline M. Giammarco, Principal and Chief Compliance Officer at Stone Point Capital; James D. Carey, Principal at Stone Point Capital; Fayez S. Muhtadie, Senior Principal at Stone Point Capital; Olivier Sarkozy, Founder and Managing Partner of Further Global; and Daniel Brenhouse, Principal at Permira.

Read More: Equifax Launches Innovative New Solutions for Credit Monitoring and Identity Theft Protection

Related posts

OneVest Bolsters its North American Sales Team with the Addition of Wealthtech Veterans from InvestCloud and FNZ

Business Wire

Miami Dolphins and Broxel Announce Multi-Year Agreement

Fintech News Desk

Topography Health Launches With $27.5m Funding to Empower Community Physicians to Run Clinical Drug Trials

Fintech News Desk
1